Endocrine Abstracts

Purpose: Osteopathy is an emerging complication of acromegaly characterized by increased bone turnover, deterioration in bone microarchitecture and high risk of vertebral fractures (VFs). In somatostatin analog (SSA)-resistant patients (pts), Pegvisomant (PegV) and Pasireotide LAR (Pasi) are used for acromegaly treatment, but their effect on skeletal health is still not defined.Methods: In a longitudinal international multicenter study, we evaluated inci...

Introduction: Bilateral sampling of the inferior petrosal sinuses (IPSS) is considerate actually the best diagnostic test for Cushing.Patients and methods: We retrospectively reviewed our series of patients undergone IPSS for Cushing disease and we compared the difference between central and peripheral ACTH gradient in basal condition and after CRH stimulation in cases of localization of the tip of the catheters inside the inferior petrosal sinus or at t...

Aim: To evaluate calcium and bone metabolism in a monocentric series of acromegaly patients (pts), treated with pegvisomant (PEG) alone or in association to long acting somatostatine analogs.Patients and methods: All pts with at least 24 consecutive months PEG treatment (alone or in combination with SSA) were enrolled. All pts had been tested at least twice/year for biochemical acromegaly-disease evaluation and annually for calcium metabolism and for bon...

Background and objective: Atypical pituitary adenomas (APA), in 2004, were defined according to WHO classification, as those with Ki-67>3%, excessive p53 expression and increased mitotic activity and invasive behaviour. The real usefulness of this classification is still controversial, so we reviewed compared clinical and prognostic features in our typical and atypical pituitary adenomas.Patients and methods: We retrospectively reviewed 343 consecuti...

GEP NETs, especially gastrinomas, occur in 40–70% of MEN1 patients and represent the main cause of death in these patients.We aim to investigate the efficacy of lanreotide autogel (ATG) in the treatment of MEN1-related gastrinomas.We report a monocentric series of seven MEN1 patients (three M, and four F) treated with lanreotide ATG (120 mg/4 weeks) for a mean period of 62.1 months. Plasma gastrin levels have been measured at ...

The IGF1 response to recombinant human growth hormone (rhGH) showed some individual variability and the responsible factors for this behavior remain unknown. Some studies have emphasized the possible role of isoforms of the GH receptor (GHR), showing conflicting results.Therefore, we investigated the possible influence of the isoforms of the GHR to the diagnosis of GHD and in determining adult hormone replacement therapy responsiveness.<p class="abst...

Anabolic therapies represent a major advance in the management of severe osteoporosis. Parathyroid hormone (PTH) and human recombinant PTH peptide 1–34 (Teriparatide) demonstrated an increase in bone mineral density and a significant reduction in vertebral fractures in patients with osteoporosis when given for 18–24 months. The intermittent administration of PTH or teriparatide stimulates osteoblastic function, improves bone architecture and has an additional analges...

Introduction: Everolimus is an oral mTOR inhibitor that exerts antineoplastic effects inhibiting cell proliferation, survival and angiogenesis. Its activity in advanced neuroendocrine tumors (NETs) has been demonstrated in controlled trials and everolimus was approved by the FDA for the treatment of progressive, advanced pNETs in May 2011.Materials and methods: We treated with everolimus, at the dosage of 10 mg once daily, 14 patients with advanced, prog...

Introduction: The main goal in the treatment of acromegaly is achieving biochemical and tumor mass control. Therapeutic options include surgery, medical treatment and, in selected cases, radiotherapy. A GH receptor (GHR) variant that differs for the genomic retention or exclusion (d3GHR) of exon 3 is present in about 50% of general population and its presence is related to a greater sensitivity to GH.Materials and methods: We describe a series of 118 pat...

GH deficiency (GHD) and excess of glucocorticoids are associated with increased risk of fragility fractures. Most adult GHD patients have other pituitary deficiencies, but it is unclear whether these deficiencies or their overreplacement therapies may influence the bone disease occurring in GHD. The aim of this study was to evaluate whether the prevalence of vertebral fractures may be influenced by glucocorticoid replacement therapy in hypopituitary males with GHD. We studied ...